Drug Interactions With Extended-Release Exenatide
Extended-Release Exenatide and HypoglycemiaWhen using extended-release exenatide by itself, it is not particularly likely to cause dangerously low blood sugar levels (hypoglycemia). However, combining it with insulin, or oral medications that increase insulin production, appears to increase this risk. Such medications include:
- Insulin of any type
- Meglitinides, such as:
- Sulfonylureas (or sulfonylurea combination medications), such as:
- Chlorpropamide (Diabinese®)
- Glimepiride (Amaryl®)
- Glimepiride and pioglitazone (Duetact®)
- Glimepiride and rosiglitazone (Avandaryl®)
- Glipizide (Glucotrol®, Glucotrol XL®)
- Glipizide and metformin (Metaglip®)
- Glyburide (DiaBeta®, Micronase®, Glynase®)
- Glyburide and metformin (Glucovance®)
- Tolazamide (Tolinase®)
- Tolbutamide (Orinase®).
If you combine extended-release exenatide with any of the previously listed medications that increase the risk of low blood sugar levels, you will probably need to monitor your blood sugar levels more closely. Your healthcare provider may also want to lower the dosage of your other medication (the insulin, meglitinide, or sulfonylurea) when you start using extended-release exenatide.